Metabolic management of ischaemic heart disease.
The present review summarizes the available information on the effects of the three major classes of antianginal agents (nitrates, calcium and beta-blockers) on myocardial energy metabolism. It also discusses the role of some new molecules (L-carnitine, trimetazidine and ranolazine) that have been proposed as an alternative pharmacological approach for the metabolic management of cardiac ischaemic syndromes.
Chierchia
S L
SL
Istituto Scientifico H San Raffaele, Milan, Italy.
Fragasso
G
G
D000083:Acetanilides; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000787:Angina Pectoris / Q000188:drug therapy*; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D002331:Carnitine / Q000627:therapeutic use; D004734:Energy Metabolism / Q000187:drug effects; D006801:Humans; D009206:Myocardium / Q000378:metabolism*; D005996:Nitroglycerin / Q000627:therapeutic use*; D010879:Piperazines / Q000627:therapeutic use; D000069458:Ranolazine; D014292:Trimetazidine / Q000627:therapeutic use
D000083:Acetanilides; D000319:Adrenergic beta-Antagonists; D002121:Calcium Channel Blockers; D010879:Piperazines; D000069458:Ranolazine; D005996:Nitroglycerin; D014292:Trimetazidine; D002331:Carnitine